Please assess the completion status of the following clinical trial:

Trial Title: Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC), including any of the following histologic subtypes:~  * Squamous cell carcinoma~ * Adenocarcinoma (including bronchoalveolar cell carcinoma)~ * Large cell anaplastic carcinoma (including giant and clear cell carcinoma)~* Stage IIIA disease OR selected stage IIIB disease~  * T1-2, N2 disease OR T3, N2 or T4, N0-N2 disease (if based on tumor closeness to the carina, invasion of the mediastinum, or invasion of the chest wall)~    * Contralateral mediastinal disease (N3) allowed if all gross disease can be encompassed in the radiation boost field~* Tumors adjacent to a vertebral body allowed unless there is demonstrable bone invasion~  * All gross disease must be able to be encompassed in the radiation boost field~ * No direct invasion of a vertebrae body~* Unresectable or inoperable disease~* Measurable disease~* Suitable for radiotherapy, as deemed by the radiation oncologist~* No scalene, supraclavicular, or contralateral hilar node involvement~* Pleural effusion allowed provided it is transudate, cytologically negative, and non-bloody, and, according to the radiation oncologist, the tumor can be encompassed within a reasonable radiation field~  * Pleural effusion seen on chest CT scan, but not on chest x-ray, that is too small to tap is allowed~ * No exudative, bloody, or cytologically malignant effusions~* No known brain metastases~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* ANC ≥ 1,500/mm³~* Platelet count ≥ 75,000/mm³~* Total bilirubin ≤ 1.5 mg/dL~* Creatinine normal~* Alkaline phosphatase AND AST or ALT meeting 1 of the following criteria:~  * Alkaline phosphatase normal AND AST or ALT ≤ 5 times upper limit of normal (ULN)~ * Alkaline phosphatase ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN~ * Alkaline phosphatase ≤ 5 times ULN AND AST or ALT normal~* Able to swallow oral medications~* No peripheral neuropathy \> grade 1~* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to selenomethionine or agents formulated with Cremophor EL~* No concurrent uncontrolled illness including, but not limited to, any of the following:~  * Ongoing or active infection~ * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Clinically significant cardiac arrhythmia~ * Psychiatric illness or social situations that would limit compliance with study requirements~* No currently active second malignancy other than non-melanoma skin cancer~  * Patients are considered not to have an active malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse~* Not pregnant~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~* At least 2 weeks since prior formal exploratory thoracotomy (N2 node identified making patient ineligible for surgery)~* No prior chemotherapy or radiotherapy for NSCLC~* No prior taxanes or platinum drugs~* No other concurrent investigational agents or anticancer therapy~* No concurrent combination antiretroviral therapy for HIV-positive patients~* No other concurrent chemotherapy or hormonal therapy, except for the following:~  * Steroids administered for adrenal failure or septic shock~ * Hormones administered for non-disease-related conditions (e.g., insulin for diabetes)~ * Glucocorticosteroids administered as antiemetics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- CPSR (Type: EXPERIMENTAL): Concurrent Carboplatin, Paclitaxel and Selenomethionine in Combination with Radiation

Based on this trial design, predict the completion outcome and termination type (if applicable).